Iohexol versus metrizamide for lumbar myelography: preliminary report of double-blind trial.
Lumbar myelography was performed in 38 patients; 19 received iohexol (an investigational aqueous contrast agent) and 19 received metrizamide. Iohexol is stable in solution, which is not the case with metrizamide. There was no other significant difference in diagnostic utility or quality between the two media. However, there was considerable postmyelography morbidity in the metrizamide group, but no postmyelography morbidity in the iohexol group. Preliminary clinical evidence suggests that iohexol is significantly superior to metrizamide as a contrast agent for lumbar myelography.
D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007463:Iodobenzoates; D007472:Iohexol; D008161:Lumbosacral Region; D008793:Metrizamide / Q000009:adverse effects; D009192:Myelography / Q000009:adverse effects / Q000379:methods*; D009325:Nausea / Q000139:chemically induced; D011843:Radiculopathy / Q000000981:diagnostic imaging; D014283:Triiodobenzoic Acids
D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D008793:Metrizamide